Literature DB >> 856918

Antigenicity of cholera toxoid in humans.

R Germanier, E Fürer, S Varallyay, T M Inderbitzin.   

Abstract

A cholera toxoid was produced by heating of a purified cholera toxin and treatment of the resulting toxoid procholeragenoid with a formaldehyde solution. When given subcutaneously and intramuscularly to volunteers in doses of 3-100 microng, the toxoid produced no noteworthy side effects, but the injections produced a dose-dependent rise in level of toxin-neutralizing antibodies in serum. Administration of toxoid in combination with whole-cell vaccine induced antitoxin levels that seemed to be higher than those induced by toxoid alone, but statistical analysis revealed a significant difference only between titers after administration of 10 microng of toxoid alone and those after administration of 10 microng of toxoid in combination with whole-cell vaccine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856918     DOI: 10.1093/infdis/135.4.512

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers.

Authors:  S Migasena; P Pitisuttitham; P Suntharasamai; B Prayurahong; W Supanaranond; V Desakorn; R E Black
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

Review 2.  Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells.

Authors:  K L Richards; S D Douglas
Journal:  Microbiol Rev       Date:  1978-09

Review 3.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

4.  Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid.

Authors:  E Fürer; S J Cryz; F Dorner; J Nicolet; M Wanner; R Germanier
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

6.  Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease.

Authors:  R S Rappaport; G Bonde
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.